Evidence map›Paper›PMID 39679304›Full record

ReviewWorld journal of gastroenterology2024

Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease.

Bhupesh Singla

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bhupesh SinglaPharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN 38103, United States. bsingla@uthsc.edu.

Funding

Regulation of Lymphangiogenesis by Thrombospondin 1R00HL146954 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Bhupesh Singla · 2023 to 2024
$494k
Regulation of Lymphangiogenesis by Thrombospondin 1K99HL146954 · NHLBI · AUGUSTA UNIVERSITY · PI Bhupesh Singla · 2021 to 2021
$116k
NHLBI NIH HHS K99 HL146954NHLBI NIH HHS R00 HL146954
6 · The paper itself

Abstract

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased significantly in recent decades and is projected to increase further due to the rising obesity rates. MASLD patients are at higher risk of developing advanced liver diseases "cirrhosis and hepatocellular carcinoma" as well as liver- or cardiovascular-related mortality. Existing lipid-lowering therapies failed to reduce the risk of mortality in these patients. Therefore, there is an urgent need for pharmacotherapies that can control and even reverse this disease. Fanlian Huazhuo Formula (FLHZF) is a combination herbal preparation, and its various individual constituents regulate hepatic lipid metabolism, adipose tissue inflammation, and gut microbiota. Despite, these useful effects, limited information is available on its benefits in diet-induced hepatosteatosis. In this article, we discuss the research findings recently published about the therapeutic effects of FLHZF in suppressing MASLD development and underlying mechanisms. Utilizing a series of

Indexed as

Drugs, Chinese HerbalGastrointestinal MicrobiomeLipid MetabolismLiverAnimalsDisease Models, AnimalFatty LiverHepatocytesHumansLipogenesisMaleMiceNon-alcoholic Fatty Liver DiseasePhytotherapyDrugs, Chinese HerbalAcetyl-CoA carboxylaseAdenosine-5’-monophosphate-activated protein kinase alphaCell deathDe novo lipogenesisFanlian Huazhuo FormulaMetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID39679304
PMCPMC11612710

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.